NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-08-31
Reading CRL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Management is running behind on a stated commitment.
Charles River Laboratories grows revenue despite a tough market, with 1.2% growth last quarter. The company expects EPS near $11.3 in 2026 and repurchased $200 million of stock in Q1. Its M&A strategy supports growth and portfolio focus. Profitability is improving with positive earnings surprises.
Revenue is expected to decline about 1% in 2026. The company faces regulatory and litigation risks. Profit margins and earnings could weaken if growth falters or divestitures disrupt operations. Stock valuation is high relative to current growth trends.
The stock price is about 14% above our valuation level and 9% below the Street median. Analysts expect revenue to decline about 2% next year. Our view is more cautious on growth but aligned with the market on earnings.
Breaks if: EPS falls below $10.8 in FY26
Breaks if: YoY revenue growth falls below -1.5% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on refining its portfolio and enhancing client experiences. The current thesis state is intact, supported by strong recent financial performance, but with medium confidence due to elevated risks.
The market appears to price CRL at a premium compared to its peers, indicating that expectations are somewhat high. There is a slight expectations gap, suggesting that while the stock is viewed as justified, it may be considered expensive relative to its industry.
Management has shown robust earnings quality, but recent financial performance has been mixed, with some segments experiencing flat or negative organic revenue growth. The near-term risk of missing earnings is low, but there is a history of significant misses that could affect confidence.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
Yes, our read has strengthened. The latest earnings beat supports the outlook. The company is enhancing its client experience and scientific portfolio through vaccine development. It is also refining its portfolio by completing divestitures. There are no new threats to the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on strengthening client relationships and expanding scientific capabilities to capture more R&D spending.
Stated as a priority in 3 of last 4 quarters. Management highlighted collaborations and AI-enabled solutions to deepen client relationships and enhance the scientific portfolio. While revenue showed modest organic growth in some segments, overall organic revenue was flat to slightly negative, indicating ongoing efforts with limited broad revenue impact so far.
“Joined Eli Lilly's TuneLab AI/ML platform and collaborated with Arovella Therapeutics to enhance client relationships and scientific portfolio.”
“Focus remains on enhancing clients' experience and strengthening scientific portfolio to increase long-term shareholder value.”
“Making significant progress on strategic initiatives to capitalize on growth opportunities and reinforce leadership in preclinical drug development.”
Breaks if: Stock repurchases fall significantly below $200 million in Q1 2026
The long-term thesis hinges on management's ability to execute on divestitures and enhance the client experience, as well as external factors like sector performance and economic conditions. Key scenarios include the potential impact of recession fears and the performance of sector bellwethers.
Over the next 1 to 3 years, CRL's performance will depend on effective management execution and external market conditions. Not investment advice.
